Cargando…
Dilemma of belimumab therapy (dis)continuation during pregnancy: Results of a retrospective study in eudravigilance
INTRODUCTION: The first biologic authorized for systemic lupus erythematosus (SLE) up to this date, belimumab, is currently not recommended for use during pregnancy due to lack of data. Provided that the health of the child begins with the health of the mother, pregnant patients face the dilemma of...
Autores principales: | Ghalandari, Nafise, Crijns, Hubertina JMJ, Dolhain, Radboud JEM, Hazes, Johanna MW, van Puijenbroek, Eugene P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939929/ https://www.ncbi.nlm.nih.gov/pubmed/36448410 http://dx.doi.org/10.1177/09612033221143286 |
Ejemplares similares
-
Reported congenital malformations after exposure to non‐tumour necrosis factor inhibitor biologics: A retrospective comparative study in EudraVigilance
por: Ghalandari, Nafise, et al.
Publicado: (2022) -
Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy
por: Ghalandari, Nafise, et al.
Publicado: (2022) -
Active counselling and well-controlled disease result in a higher percentage of women with rheumatoid arthritis that breast feed: results from the PreCARA study
por: Kemper, Erik, et al.
Publicado: (2022) -
Mannose-binding lectin does not explain the course and outcome of pregnancy in rheumatoid arthritis
por: van de Geijn, Fleur E, et al.
Publicado: (2011) -
Modern treatment approach results in low disease activity in 90% of pregnant rheumatoid arthritis patients: the PreCARA study
por: Smeele, Hieronymus TW, et al.
Publicado: (2021)